Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045877 · ClinicalTrials.gov registry record · Phase 2
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
A Phase 2 study, sponsored by Chiron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00045877 is a Phase 2 study that has completed, run by Chiron Corporation.
The verdict
NCT00045877, a Phase 2 study, has completed, sponsored by Chiron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
Interventions
- DRUG Recombinant Human Interleukin-2 and Rituximab
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045877
The ClinicalTrials.gov registry entry for NCT00045877 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Chiron Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Interleukin-2 and Rituximab is the first listed.
NCT00045877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045877 about?
NCT00045877 is a clinical study titled "Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments". The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
What is the current status of trial NCT00045877?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00045877?
The interventions under investigation include: Recombinant Human Interleukin-2 and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00045877?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.